TIRZEPATIDE May Aid Weight Loss in Diabetes Patients
Patients with obesity may require medication to achieve substantial weight reduction.The type 2 diabetes drug TIRZEPATIDE is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptor agonist.That has been reported to induce weight reduction in patients with diabetes.Whether Tirzepatide can induce weight reduction in patients without diabetes has not been assessed in this international phase. 3 double-blind randomized, trial, 2539 adults with obesity or with overweight, plus a weight-related complication and without diabetes, were assigned to receive subcutaneous TIRZEPATIDE once weekly at a dose of 5, 10 or 15 milligrams or placebo.
In addition to lifestyle intervention, the first co-primary endpoint the percentage of weight change from baseline to week, 72 favored, all doses of TIRZEPATIDE over placebo, in particular, mean weight reduction, ranged from fifteen percent to twenty one percent, with TIRZEPATIDE as compared with three percent with placebo.
Tirzepatide Shows Sustained Weight Reduction in Adults
For the second co-primary endpoint, the percentage of participants who lost at least five percent of their body weight by week, 72, all three doses were again superior to placebo.The most common adverse events with TIRZEPATIDE were gastrointestinal, including nausea, diarrhea and constipation.These events were most often transient and mild to moderate in severity and occurred mainly during dose escalation.The authors conclude that all three doses of TIRZEPATIDE conferred meaningful and sustained weight reduction in adults with obesity without diabetes,